Jeffrey T Billheimer

6623981, Sep 23, 2003

Jan 26, 1999

09/237061

Jeffrey T. Billheimer - West Chester PA
Dietmar A. Seiffert - Boothwyn PA
Leah A. Breth - Newark DE
Timothy C. Burn - Hockessin DE
Ira B. Dicker - Wilmington DE
Henry J. George - Newark DE
Gregory F. Hollis - Wilmington DE
Jeannine M. Hollis - Wilmington DE
Jennifer E. Kochie - Hockessin DE
Karyn T. ONeil - Kennett Square PA

Bristol-Myers Squibb Company - Princeton NJ

G01N 33553

436518, 436540, 436546, 436164, 436811, 435 71, 435 72, 435 79, 435 792, 435 793, 435 794, 435 795, 435 28, 435174, 435968

This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays. This invention also relates to procedures for treating blood samples, which dissociate antibodies to GPIIb/IIIa from the platelet surface, thereby increasing the recovery from the platelet supernatant.

7569590, Aug 4, 2009

Sep 18, 2007

11/856754

Dong Cheng - Furlong PA, US
Jeffrey T. Billheimer - West Chester PA, US
James J. Devenny - Wayne PA, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 31/44
A61K 31/496

514336, 51425505, 514256, 514909

The present application describes methods of treating obesity using DGAT-1 inhibitors according to Formula I:.

20060100146, May 11, 2006

Aug 15, 2005

11/204427

Stephen Sturley - New York NY, US
Aaron Turkish - New York NY, US
Jeffrey Billheimer - West Chester PA, US
Debra Cromley - Pittsgrove NJ, US

A61K 38/26
A61K 31/685
A61K 31/553
A61K 31/366
A61K 31/19

514012000, 514078000, 514457000, 514460000, 514557000, 514571000, 514356000, 514211130

This invention provides methods for treating a subject afflicted with acne or another sebaceous gland disorder comprising administering to the subject a therapeutically effective amount of an agent which inhibits acyl-CoA wax alcohol acyltransferase 1 (AWAT1) and/or acyl-CoA wax alcohol acyltransferase 2 (AWAT2), thereby treating the subject. This invention further provides related articles of manufacture and methods.

20120138784, Jun 7, 2012

Jan 13, 2012

13/350207

Daniel J. Rader - Philadelphia PA, US
Jeffrey T. Billheimer - West Chester PA, US

H01J 49/26
G01T 1/00

250282, 250395

Methods and compositions for the in vivo measurement of reverse cholesterol transport are provided.

51662140, Nov 24, 1992

Jun 4, 1990

7/533241

Jeffrey T. Billheimer - West Chester PA
Peter J. Gillies - Hockessin DE
C. Anne Higley - Newark DE
Thomas P. Maduskuie - Wilmington DE
Ruth R. Wexler - Wilmington DE

Du Pont Merck Pharmaceutical Company - Wilmington DE

A61N 31415
C07D23366

514341

This invention relates to imidazoles as inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT), processes for their preparation, and their use as antihypercholesterolemic agents or antiatherosclerotic. The compounds for use in the described method are compounds of Formula (I): ##STR1## wherein R. sup. 1 and R. sup. 2 are selected independently from H, C. sub. 1 -C. sub. 8 alkyl, C. sub. 3 -C. sub. 8 branched alkyl, C. sub. 3 -C. sub. 7 cycloalkyl, C. sub. 4 -C. sub. 10 cycloalkylalkyl, C. sub. 7 -C. sub. 14 araalkyl, phenyl optionally substituted with 1 to 3 groups selected from F, Cl, Br, OH, C. sub. 1 -C. sub. 4 alkoxy, C. sub. 1 -C. sub. 4 alkyl, C. sub. 3 -C. sub. 8 branched alkyl, CH. sub. 3 S(O). sub. r, NO. sub. 2, CF. sub. 3, or NR. sup. 7 R. sup. 8 ; R. sup. 3 is H, C. sub. 1 -C. sub. 6 alkyl, allyl, benzyl, or phenyl optionally substituted with F, Cl, CH. sub. 3, CH. sub. 3 O, or CF. sub. 3 ; R. sup.

54911524, Feb 13, 1996

Mar 23, 1994

8/216723

Richard G. Wilde - Newark DE
Soo S. Ko - Wilmington DE
Jeffrey T. Billheimer - West Chester PA

The Du Pont Merck Pharmaceutical Company - Wilmington DE

A61K 3138
A61K 3144
C07D40512
C07D40912

514336

The present invention provides compounds of Formula I, ##STR1## or a pharmaceutically acceptable salt forms thereof, which are inhibitors of acyl-Coenzyme A: cholesterol O-acyltransferase (ACAT), pharmaceutical compositions containing such compounds, processes for the preparation of such compounds, and the use of such compounds as antihypercholesterolemic and/or antiatherosclerotic agents.

53107489, May 10, 1994

May 11, 1992

7/881034

Richard G. Wilde - New Castle DE
C. Anne Higley - Newark DE
Jeffrey T. Billheimer - West Chester PA
Ruth R. Wexler - Wilmington DE

The Du Pont Merck Pharmaceutical Company - Wilmington DE

C07D40312
A61K 31415

514397

Disclosed are imidazoles as inhibitors of acylCoA:cholesterol acyltransferase (ACAT), processes for their preparation, pharmaceutical compositions, and their use as antihypercholesterolemics and/or antiatherosclerotics.

54280419, Jun 27, 1995

Mar 4, 1992

7/836323

Jeffrey T. Billheimer - Wilmington DE
George A. Boswell - Wilmington DE
Indawati De Lucca - Wilmington DE
Spencer Drummond - Wilmington DE
Peter J. Gillies - Hockessin DE
James M. Trzaskos - Boothwyn PA

The Du Pont Merck Pharmaceutical Company - Wilmington DE

A61K 31415
A61K 31445
C07D23366
C07D40110

514316

Provided are bis-trifluoromethyl-substituted imidazolines as inhibitors of Acyl-CoA:Cholesterol Acyltransferase (ACAT), processes for their preparation, pharmaceutical compositions, and therapeutic methods for their use as antihypercholesterolemic or antiatherosclerotic agents.